8-K: Femasys Inc. Faces Nasdaq Delisting Threat Over Sub-$1.00 Stock Price

Femasys Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting if not resolved by January 12, 2026.

Summary

• Femasys Inc. received a notice from The Nasdaq Stock Market on July 16, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2).
• The non-compliance is due to the company's common stock bid price remaining below $1.00 per share for 30 consecutive business days.
• This notification does not immediately affect the listing or trading of Femasys' common stock on The Nasdaq Capital Market.
• The company has a 180-calendar day grace period, until January 12, 2026, to regain compliance.
• To regain compliance, the common stock's minimum bid price must close at or above $1.00 per share for at least ten consecutive business days during this period.
• If compliance is not regained by January 12, 2026, Femasys may be eligible for an additional 180-calendar day compliance period, provided it meets other initial listing standards and intends to cure the deficiency, potentially through a reverse stock split.
• Failure to regain compliance by the end of the grace period(s) will result in the common stock becoming subject to delisting.
• The company has the right to appeal a delisting determination to a Nasdaq hearings panel.

Sentiment

Score: 2

Explanation: The document indicates a significant negative event (Nasdaq non-compliance and potential delisting) with no immediate positive offsets, leading to high uncertainty and risk for investors.

Negatives

• Femasys Inc. is not in compliance with Nasdaq's Minimum Bid Price Requirement, risking potential delisting.
• The company's stock price has been below $1.00 for 30 consecutive business days, indicating sustained low market valuation.
• There is no assurance that the company will be able to regain compliance with the Minimum Bid Price Requirement or other Nasdaq Listing Rules.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with the Minimum Bid Price Requirement.
• Potential need for a reverse stock split, which can be dilutive or negatively perceived by investors.
• Uncertainty regarding the company's ability to meet other Nasdaq Listing Rules.

Future Outlook

Femasys Inc. intends to monitor the closing bid price of its common stock and may consider available options to regain compliance, including initiating a reverse stock split. However, there is no assurance that compliance will be regained.

Management Comments

• "The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, including initiating a reverse stock split."
• "However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules."

Industry Context

This situation is common for smaller public companies, particularly in the biotechnology or medical device sectors, which may experience periods of low stock valuation due to clinical trial outcomes, regulatory hurdles, or market sentiment. Maintaining Nasdaq listing is crucial for liquidity and investor confidence.

Stakeholder Impact

• Shareholders face increased risk of delisting, which could severely impact stock liquidity and valuation.
• Potential reverse stock split could lead to a reduction in the number of shares outstanding, which may be perceived negatively by some investors.
• The company's ability to attract new investors and raise capital may be hindered by the delisting threat.

Next Steps

• Femasys Inc. will monitor its common stock's closing bid price.
• The company may consider options such as a reverse stock split to regain compliance.
• If delisted, the company may appeal the determination to a Nasdaq hearings panel.

Key Dates

Recommendation

Keywords

Nasdaq, delisting, minimum bid price, non-compliance, Femasys Inc., FEMY, stock market, reverse stock split, SEC filing, 8-K